FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: February 07, 2018
Mind-controlling molecules from wasp venom could someday help Parkinson's patients
After being stung by a parasitic wasp, the American cockroach loses control of its behavior, becoming host to the wasp’s egg. Days later, the hatchling consumes the cockroach alive. While this is a gruesome process for the cockroach, scientists now report in ACS’ journal Biochemistry the discovery of a new family of peptides in the wasp’s venom that could be key to controlling roach minds, and might even help researchers develop better Parkinson’s disease treatments.
Scientists have long studied venoms, such as that of the wasp, seeking out novel and potent molecules to treat disease, among other applications. In the case of the enigmatic wasp Ampulex compressa, it uses its venom in a two-pronged approach against the cockroach, with an initial sting to the thorax to paralyze the front legs and a subsequent sting directly to the brain. This second sting causes the roach first to vigorously groom itself, then to fall into a state of lethargy, allowing the wasp to do whatever it wants. This immobile state resembles symptoms of Parkinson’s disease, and both may be related to dysfunction in the dopamine pathway. In this study, Michael E. Adams and colleagues wanted to identify the ingredients in wasp venom that dictate this behavior.
The researchers milked wasps for their venom and then analyzed the components using liquid chromatography and mass spectrometry. They identified a new family of alpha-helical peptides and named them ampulexins. To test their function, the team injected the most abundant venom peptide into cockroaches. Afterward, the bugs needed, on average, a 13-volt electric shock to the foot to get them moving, while an average of 9 volts sufficed prior to the injection, suggesting the peptides help the wasp immobilize its prey. Future work will focus on identifying cellular targets of ampulexins, and potentially generating a useful animal model for the study of Parkinson’s disease treatments.
The authors acknowledge funding from the United States-Israel Binational Science Foundation, the University of California, Riverside Office of Research and Economic Development and the University of California Agricultural Experiment Station.
Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.